By Fineline Cube Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), presented compelling Phase II clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting for Saitanxin (culmerciclib), a CDK2/4/6 inhibitor, in combination with fulvestrant for patients with HR-positive, HER2-negative advanced breast cancer who had progressed on prior CDK4/6 inhibitor plus endocrine therapy.
Clinical Trial Results – Phase II Study
| Endpoint | Result | Confidence Interval | Significance |
|---|---|---|---|
| Objective Response Rate (ORR) | 32.4% | 17.4–50.5% | p<0.0001 (primary endpoint met) |
| Disease Control Rate (DCR) | 88.2% | 72.6–96.7% | Clinically meaningful |
| Clinical Benefit Rate (CBR) | 82.4% | 65.5–93.2% | Substantial patient benefit |
| Time to Response (TTR) | 3.7 months (median) | — | Rapid onset of activity |
| 10-Month PFS Rate | 61.8% | 42.3–76.4% | Promising sustained disease control |
| Patient Population | 34 efficacy-evaluable patients | Heavily pre-treated | CDK4/6i-resistant setting |
The study addresses a critical unmet need in breast cancer treatment—patients who have exhausted standard CDK4/6 inhibitor therapy and represent one of the most challenging populations to treat effectively.
Drug Profile & Mechanism of Action
- Molecule: Culmerciclib (Saitanxin) – novel CDK2/4/6 inhibitor
- Target Rationale: Simultaneous inhibition of CDK2, CDK4, and CDK6 overcomes resistance mechanisms that develop against selective CDK4/6 inhibitors
- Combination Partner: Fulvestrant (estrogen receptor degrader)
- Patient Population: HR+/HER2- advanced breast cancer post-CDK4/6 inhibitor failure
- Safety Profile: Consistent with prior studies; no new safety signals observed
Market Context & Competitive Landscape
| Aspect | Analysis |
|---|---|
| CDK4/6 Inhibitor Resistance | ~70% of HR+ breast cancer patients eventually progress on CDK4/6 inhibitors; limited effective subsequent options |
| Current Treatment Options | Chemotherapy, PI3K inhibitors, SERDs; generally lower response rates and higher toxicity |
| Saitanxin Differentiation | First-in-class CDK2/4/6 triple inhibition approach specifically designed to overcome CDK4/6i resistance |
| Market Opportunity | Estimated 45,000-50,000 CDK4/6i-resistant HR+ breast cancer patients annually in major markets |
| Competitive Environment | Multiple companies developing next-generation CDK inhibitors; Saitanxin among first to report robust clinical data in resistant setting |
Strategic Implications & Development Outlook
- Regulatory Pathway: Strong Phase II data supports potential accelerated approval discussions with FDA and NMPA
- Commercial Premium: High response rate in resistant population supports significant pricing power
- Global Expansion: ASCO presentation validates international development strategy for Chinese-developed oncology asset
- Pipeline Validation: Success reinforces Sino Biopharmaceutical’s oncology innovation capabilities beyond traditional generics
- Next Steps: Phase III confirmatory trial likely to initiate based on compelling Phase II results
The 32.4% ORR represents a substantial improvement over historical benchmarks in this heavily pre-treated population, where response rates typically range from 10-20% with available therapies.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial results, regulatory pathways, and commercial expectations for Saitanxin. Actual results may differ due to risks including clinical trial variability, regulatory decisions, and competitive dynamics.-Fineline Info & Tech